---
figid: PMC3906683__nihms-546899-f0001
figlink: /pmc/articles/PMC3906683/figure/F1/
number: F1
caption: 'Schematic representation of the biological hypothesis supporting combination
  spironolactone (SPIRO) plus endothelin type-A receptor (ETA) antagonism for the
  treatment of PAH. Stimulation of pulmonary smooth muscle cells (PSMC) ETA and endothelin
  type-B receptor (ETB) are the major and minor signaling pathways, respectively,
  that modulate endothelin-1 (ET-1)-dependent pulmonary vasoconstriction in PAH. In
  contrast, pulmonary artery endothelial cell (PAEC) ETB stimulation by ET-1 promotes
  pulmonary vasodilation. In PAH, hyperaldosteronism is associated with a pulmonary
  vasculopathy that is due, in part, to increased oxidant stress levels that inhibits
  ETB function. Therefore, 2 potential treatment targets within the aldosterone-endothelin
  receptor axis are exposed: ETA to inhibit the major pulmonary vasoconstrictor pathway
  and the mineralocorticoid receptor (MR) to preserve ETB-dependent vasodilation.'
pmcid: PMC3906683
papertitle: Effectiveness of Spironolactone Plus Ambrisentan for Treatment of Pulmonary
  Arterial Hypertension (from the [ARIES] Study 1 and 2 Trials).
reftext: Bradley A. Maron, et al. Am J Cardiol. ;112(5):720-725.
pmc_ranked_result_index: '143492'
pathway_score: 0.9238858
filename: nihms-546899-f0001.jpg
figtitle: Schematic representation of the biological hypothesis supporting combination
  spironolactone (SPIRO) plus endothelin type-A receptor (ETA) antagonism for the
  treatment of PAH
year: ''
organisms:
- Human immunodeficiency virus
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3906683__nihms-546899-f0001.html
  '@type': Dataset
  description: 'Schematic representation of the biological hypothesis supporting combination
    spironolactone (SPIRO) plus endothelin type-A receptor (ETA) antagonism for the
    treatment of PAH. Stimulation of pulmonary smooth muscle cells (PSMC) ETA and
    endothelin type-B receptor (ETB) are the major and minor signaling pathways, respectively,
    that modulate endothelin-1 (ET-1)-dependent pulmonary vasoconstriction in PAH.
    In contrast, pulmonary artery endothelial cell (PAEC) ETB stimulation by ET-1
    promotes pulmonary vasodilation. In PAH, hyperaldosteronism is associated with
    a pulmonary vasculopathy that is due, in part, to increased oxidant stress levels
    that inhibits ETB function. Therefore, 2 potential treatment targets within the
    aldosterone-endothelin receptor axis are exposed: ETA to inhibit the major pulmonary
    vasoconstrictor pathway and the mineralocorticoid receptor (MR) to preserve ETB-dependent
    vasodilation.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ALDOA
  - ALDOB
  - ALDOC
  - EDNRB
  - NR4A3
  - EDN1
genes:
- word: ALDO
  symbol: ALDO
  source: bioentities_symbol
  hgnc_symbol: ALDOA
  entrez: '226'
- word: ALDO
  symbol: ALDO
  source: bioentities_symbol
  hgnc_symbol: ALDOB
  entrez: '229'
- word: ALDO
  symbol: ALDO
  source: bioentities_symbol
  hgnc_symbol: ALDOC
  entrez: '230'
- word: ETB
  symbol: ETB
  source: hgnc_alias_symbol
  hgnc_symbol: EDNRB
  entrez: '1910'
- word: Minor
  symbol: MINOR
  source: hgnc_alias_symbol
  hgnc_symbol: NR4A3
  entrez: '8013'
- word: ET-1
  symbol: ET1
  source: hgnc_alias_symbol
  hgnc_symbol: EDN1
  entrez: '1906'
chemicals: []
diseases: []
figid_alias: PMC3906683__F1
redirect_from: /figures/PMC3906683__F1
figtype: Figure
---
